Steven K. Grinspoon

Oct 8, 2024 | healio.com | Michael Monostra |Richard Smith |Steven K. Grinspoon

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: In REPRIEVE, incidence rates for new-onset diabetes were highest for people with HIV and three or more metabolic risk factors. Similar diabetes incidence rates were seen in the pitavastatin and placebo groups.

May 1, 2024 | nejm.org | Steven K. Grinspoon |Heather Ribaudo |Pamela Douglas

NotesThe views expressed in this letter are those of the authors and do not necessarily represent the views of the National Heart, Lung, and Blood Institute or the National Institute of Allergy and Infectious Diseases (NIAID), the National Institutes of Health (NIH), or the U.S. Department of Health and Human Services. This letter was updated on May 2, 2024, at NEJM.org.

Nov 14, 2023 | healio.com | Erik Swain |Richard Smith |Michael Lu |Steven K. Grinspoon

You've successfully added Cardiology: Imaging to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: In patients with HIV at low to moderate CVD risk, pitavastatin lowered noncalcified plaque volume and reduced risk for plaque progression vs. placebo.